Chemical structure of Giredestrant

selective ER degrader (SERD) + full antagonist

oral (30 mg QD), Ph. III for ER+, HER2- BC

from profiling >4k cmpds for desired MoA

Journal of Medicinal Chemistry

Genentech, San Francisco, US

The Genentech next generation oral SERD (selective estrogen receptor degrader) and full antagonist, giredestrant (GDC-9545), is a potential best-in-class Ph. III candidate for ER+, HER2- breast cancer (NCT04546009). It is the third…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.